News stories about Teleflex (NYSE:TFX) have been trending somewhat positive on Wednesday, Accern reports. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Teleflex earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave news articles about the medical technology company an impact score of 47.0323761354607 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Teleflex (TFX) Lowered to C+ at TheStreet (americanbankingnews.com)
- Insider Selling: Teleflex Incorporated (TFX) Director Sells 2,500 Shares of Stock (americanbankingnews.com)
- Teleflex to Present at Needham & Company’s 17th Annual Healthcare Conference (finance.yahoo.com)
- Teleflex (TFX) Cut to Hold at ValuEngine (americanbankingnews.com)
- Teleflex Incorporated (TFX) Expected to Announce Quarterly Sales of $568.96 Million (americanbankingnews.com)
Shares of Teleflex (TFX) traded down $1.66 during trading on Wednesday, hitting $265.69. The company had a trading volume of 282,551 shares, compared to its average volume of 316,611. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.33 and a quick ratio of 1.51. Teleflex has a 1 year low of $191.04 and a 1 year high of $288.78. The firm has a market cap of $12,000.22, a P/E ratio of 81.76, a P/E/G ratio of 1.96 and a beta of 1.22.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Friday, March 2nd will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, March 1st. This represents a $1.36 annualized dividend and a dividend yield of 0.51%. Teleflex’s dividend payout ratio is presently 41.59%.
TFX has been the subject of several research analyst reports. Deutsche Bank lowered Teleflex from a “buy” rating to a “hold” rating and set a $251.00 price target for the company. in a research report on Tuesday, November 14th. ValuEngine cut Teleflex from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Stephens reiterated a “buy” rating and issued a $300.00 price objective on shares of Teleflex in a research note on Thursday, January 18th. Leerink Swann cut their price target on Teleflex from $321.00 to $300.00 and set an “outperform” rating on the stock in a research note on Friday, February 23rd. Finally, TheStreet cut Teleflex from an “a-” rating to a “c+” rating in a research report on Monday. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company. Teleflex presently has an average rating of “Hold” and an average price target of $281.56.
In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $248.96, for a total value of $49,792.00. Following the completion of the transaction, the director now directly owns 8,080 shares of the company’s stock, valued at approximately $2,011,596.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director George Babich, Jr. sold 2,500 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $283.11, for a total transaction of $707,775.00. Following the completion of the transaction, the director now directly owns 9,581 shares of the company’s stock, valued at $2,712,476.91. The disclosure for this sale can be found here. Insiders have sold a total of 14,259 shares of company stock valued at $3,760,536 over the last three months. Corporate insiders own 2.39% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first reported by BBNS and is the property of of BBNS. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://baseballnewssource.com/2018/03/14/teleflex-tfx-earning-somewhat-favorable-news-coverage-analysis-shows/1927083.html.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.